Canada · Delayed Price · Currency is CAD Medexus Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2027
-
First quarter results showed strong revenue and EBITDA growth, led by GRAFAPEX's record performance and broad adoption, especially in the adult segment. Strategic expansion in Allo-HSCT and stable performance from established products support a positive outlook.
Fiscal Year 2026
-
FY2026 saw GRAFAPEX drive growth, offsetting declines from Gleolan and Rupall, with net revenue at $99.3M and adjusted EBITDA at $16.5M. GRAFAPEX is projected to reach $30–$32M in FY2027, while established products are expected to remain stable.
-
Revenue and EBITDA remain stable, with growth now driven by GRAFAPEX, an orphan drug for AML and MDS showing strong early adoption and clinical outcomes. The company is focused on expanding its rare disease portfolio through accretive acquisitions and expects to more than double revenue in the coming years.
-
A diversified pharma portfolio is driving steady revenue and EBITDA, with GRAFAPEX poised to double revenue at high margins. Strong hospital uptake, favorable reimbursement, and robust clinical data support U.S. peak sales of $100–$175 million within 3–5 years.
-
GRAFAPEX continues to drive growth, with strong adoption and improving gross margins, despite overall revenue declines due to generic competition and product returns. Cash flow and balance sheet strength have improved, supporting ongoing investments and share repurchases.
-
Graphopex outperformed expectations, driving strong adoption and positive feedback, with guidance for continued revenue growth and positive cash flow in fiscal Q3 2026. Portfolio performance was mixed, with generic competition impacting some products and gross margin improving year-over-year.
-
Q1 2026 saw strong early GRAFAPEX adoption, offsetting declines from portfolio maturity and generic competition, with $24.6M revenue and improved gross margin. GRAFAPEX is expected to drive future growth, supported by NTAP reimbursement and robust business development prospects.
Fiscal Year 2025
-
Shareholders reviewed financial statements, elected seven directors, and reappointed PwC as auditor, with all proposals approved. No questions were raised, and voting was conducted online. Forward-looking risks were referenced in regulatory filings.
-
A diversified rare disease-focused pharma is accelerating growth with the U.S. launch of GRAFAPEX, which is expected to more than double revenue and drive higher margins. The company leverages efficient M&A, a strong commercial platform, and is actively seeking late-stage assets for future expansion.
-
GRAFAPEX's U.S. launch drove strong early revenue and positive market response, with expectations for continued sequential growth and accretive contribution by fiscal Q4 2026. Fiscal 2025 saw record adjusted EBITDA and net income, while base franchises are expected to remain stable or slightly decline.
-
A diversified pharmaceutical company is leveraging its U.S. and Canadian infrastructure to drive growth, with Treosulfan (Grafapex) as a key catalyst expected to generate over $100 million in annual revenue at high margins. The business model focuses on licensing, M&A, and efficient use of existing resources, supporting steady revenue and EBITDA growth.
-
Q3 2025 saw strong revenue and profit growth, driven by IXINITY and Rupall, and supported by disciplined cost management. FDA approval and upcoming U.S. launch of GRAFAPEX, plus a successful equity raise, position the company for future growth.
-
Q2 2025 saw stable revenue, improved net income, and strong adjusted EBITDA, with cost discipline offsetting revenue declines in some products. Preparations for a potential U.S. treosulfan launch are underway, and portfolio performance was mixed, with Rupall and Metoject showing growth.
-
Fiscal Q1 2025 saw positive net income and strong adjusted EBITDA despite lower revenue, driven by cost reductions and product performance. Rupall and Metoject showed growth, while IXINITY and Rasuvo faced declines. Treosulfan FDA decision and Gleolan U.S. exit are key near-term events.
Fiscal Year 2024
-
The meeting covered financial results, director elections, and auditor reappointment, with all proposals approved. Updates highlighted the extended FDA review for Treosulfan and preparations for a potential US launch in 2025.
-
Record annual revenue and adjusted EBITDA were achieved, despite Q4 revenue and net income declines due to challenging demand and pricing pressures. Treosulfan's FDA review is progressing, with significant revenue expected in fiscal 2026. Debt reduction and cost management remain priorities.